Dec 20, 2019
seen from United States
seen from United States
seen from Malaysia
seen from United States
seen from Canada
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from China
seen from United States
seen from Germany
seen from United States
seen from Malaysia
seen from United States
seen from Taiwan
seen from Malaysia
seen from United States
seen from Türkiye
Industry Global News24 - News solution that helps you connect and engage with target audiences in Business, Healthcare, Technology, Industry Latest News, Updated News, Latest trending News on industry across the world.
Based on a new study conducted by a team of infectious disease scientists of University of Pittsburgh School of Medicine, the healthcare market was not conducive for new antibiotics targeting some of the most dangerous and drug-resistant “superbugs”.
Based on the study, the current annual sales in US for the new antibiotics to treat Carbapenem-Resistant Enterobacteriaceae (CRE) was about $101 million annually, which was short of the $1 billion. Furthermore, it was concluded, even if new anti-CRE agents were used to treat CRE infections, the market size was only $289 million.
According to lead author Cornelius J. Clancy, M.D., associate professor of medicine and director of the mycology program and Extensively Drug Resistant Pathogen Laboratory in Pitt’s Division of Infectious Diseases, if the market cannot support the new drugs against CRE, then it hints on the future of antibiotic development.
“Without antibiotics against increasingly resistant bacteria and fungi, much of modern medicine may become infeasible, including cancer chemotherapies, organ transplantation and high-risk abdominal surgeries,” he added.
Figures suggest, CRE infections cause 1.5 to 4.5 million hospitalizations globally every year. CRE is regarded as the highest priority pathogens for the development of new antibiotics. Furthermore, one of the biopharmaceutical company Achaogen was also declared bankrupt in April owning to significant losses.
Reports allege, new CRE antibiotics are prescribed to about quarter of infections that warrant them. Experts found a drop in revenue potential with financial difficulties faced by drug companies producing the new anti-CRE drugs.
“The prudent approach when fighting bacteria is to have multiple treatment options in the pipeline so that when resistance is inevitably developed to the current drug, a new antibiotic is waiting in the wings,” explained senior author M. Hong Nguyen, M.D. “But we found that market prospects will become even more daunting if more anti-CRE drugs are approved, which is bad news for infectious disease physicians and, more importantly, our patients.”
Study experts also added that clinicians and hospitals also need to adopt a different behavioral and cultural change in order to assure quicker adoption and appropriate use of new antibiotics.
Industry Global News24 - News solution that helps you connect and engage with target audiences in Business, Healthcare, Technology, Industry Latest News, Updated News, Latest trending News on industry across the world.
Based on a new study conducted by a team of infectious disease scientists of University of Pittsburgh School of Medicine, the healthcare market was not conducive for new antibiotics targeting some of the most dangerous and drug-resistant “superbugs”.
Based on the study, the current annual sales in US for the new antibiotics to treat Carbapenem-Resistant Enterobacteriaceae (CRE) was about $101 million annually, which was short of the $1 billion. Furthermore, it was concluded, even if new anti-CRE agents were used to treat CRE infections, the market size was only $289 million.
According to lead author Cornelius J. Clancy, M.D., associate professor of medicine and director of the mycology program and Extensively Drug Resistant Pathogen Laboratory in Pitt’s Division of Infectious Diseases, if the market cannot support the new drugs against CRE, then it hints on the future of antibiotic development.
“Without antibiotics against increasingly resistant bacteria and fungi, much of modern medicine may become infeasible, including cancer chemotherapies, organ transplantation and high-risk abdominal surgeries,” he added.
Figures suggest, CRE infections cause 1.5 to 4.5 million hospitalizations globally every year. CRE is regarded as the highest priority pathogens for the development of new antibiotics. Furthermore, one of the biopharmaceutical company Achaogen was also declared bankrupt in April owning to significant losses.
Reports allege, new CRE antibiotics are prescribed to about quarter of infections that warrant them. Experts found a drop in revenue potential with financial difficulties faced by drug companies producing the new anti-CRE drugs.
“The prudent approach when fighting bacteria is to have multiple treatment options in the pipeline so that when resistance is inevitably developed to the current drug, a new antibiotic is waiting in the wings,” explained senior author M. Hong Nguyen, M.D. “But we found that market prospects will become even more daunting if more anti-CRE drugs are approved, which is bad news for infectious disease physicians and, more importantly, our patients.”
Study experts also added that clinicians and hospitals also need to adopt a different behavioral and cultural change in order to assure quicker adoption and appropriate use of new antibiotics.
Scientists are finding new ways to test for drug-resistant infections
Scientists are finding new ways to test for drug-resistant infections
Beta-lactam antibiotics (such as penicillin) are one of the most important classes of antibiotics, but resistance to them has grown to such an extent that doctors often avoid prescribing them in favour of stronger drugs.
Scientists from the University of York modified an antibiotic from the beta-lactam family so that it can be attached to a sensor, enabling them to detect the presence of bacteria…
View On WordPress
The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs.
The germ, a fungus called Candida auris, preys on people with weakened immune systems, and it is quietly spreading across the globe. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa.
Recently C. auris reached New York, New Jersey and Illinois, leading the federal Centers for Disease Control and Prevention to add it to a list of germs deemed “urgent threats.”
Candida auris
❝ Candida auris is an emerging fungus that presents a serious global health threat. CDC is concerned about C. auris for three main reasons:
❝ It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections.
It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific…
View On WordPress
For decades researchers sought evidence that antibiotics fed to farm animals transferred super bacteria to humans. Now a single study has provided a much needed smoking gun.
A superbug resistant to all known antibiotics that can cause "severe" infections or even death is spreading undetected through hospital wards across the world, scientists in Australia warned on Monday. Researchers at the University of Melbourne discovered three variants of the...